Phaseline

Companies › TenNor Therapeutics

TenNor Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TNP-2092 for injection (rifaquizinone for injection)
Rifamycin-class antibiotic (rifaquizinone)
–Phase 2Prosthetic Joint Infection (PJI)Sep 2027
Rifaquizinone (TNP-2092)
Bacterial DNA-directed RNA polymerase inhibitor; Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor
–Phase 1Periprosthetic Joint Infection (PJI)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06889701Rifaquizinone (TNP-2092)Phase 1Periprosthetic Joint Infection (PJI)Infectious diseaseJan 2027
NCT07858916TNP-2092 for injection (rifaquizinone for injection)Phase 2Prosthetic Joint Infection (PJI)Infectious diseaseSep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Suzhou HepaThera Biotech TaiMed Biologics Amplexd Therapeutics Sano Chemicals Hyundai Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.